PDCD1 and melanoma: Autoantibodies, including anti-PD-1 and thyroid-stimulating hormone (TSH)/thyroid peroxidase (TPO) antibodies, have been associated with endocrine and thyroid irAEs in melanoma and NSCLC patients [228].